ListedSMEHospital & Healthcare ServicesABH

ABH Healthcare IPO

ABH Healthcare IPO is an SME IPO raising ₹35 Cr at ₹96 – ₹102 a share. It listed on 1 Sept 2026 at ₹99, −2.9% against its issue price of ₹102, and trades at ₹66 today (−35.3% since issue). It was subscribed 2.16× in total.

102
Issue price
66
Price now
−35.3%
Since issue price
1 Sept 2026
Listed on
2.16×Subscribed (final) · all exchanges

2.2 times more demand than shares on offer

populated partly populated we hold nothing here — the tab says why

The numbers at a glance

The price they’re asking →
14.5×
Earnings multiple (derived)
₹7.05
EPS (stated)
10.7%
PAT margin, FY2026
+7%
Revenue growth, latest year
39.07%
RoNW (stated)
₹21.58
NAV per share (stated)
3.17×
Borrowings / net worth, FY2026

derived: cut-off price Rs102 / stated EPS Rs7.05 (FY2026 (year ended March 31, 2026) basic and diluted EPS, restated consolidated; post-bonus). Stated figures are as printed in the prospectus; margins, growth and the borrowing ratio are computed from its own summary table. A multiple is one lens, not a verdict.

The last few years in numbers

From the prospectus’s own summary financial table (restated consolidated). Margins and growth are computed from the stated figures; everything else is as printed.

Revenue
FY202441 Cr
FY202549 Cr
FY202653 Cr
Profit after tax
FY20242 Cr
FY20255 Cr
FY20266 Cr
EBITDA
FY20247 Cr
FY202513 Cr
FY202615 Cr
PeriodRevenueProfit after taxPAT marginNet worthBorrowings
FY202653 Cr+7%6 Cr+5%10.7%17 Cr55 Cr
FY202549 Cr+19%5 Cr+223%10.9%12 Cr42 Cr
FY202441 Cr2 Cr4.0%6 Cr36 Cr

Where the money goes

The offer →
Fresh issue — to the company35 Cr
Offer for sale — to existing holders0 Cr

Most of this issue is new shares — the money raised goes to the company, not to exiting shareholders.

How its cohort has done

131 SME issues listed in 2026 that we can price today. This is the group this issue belongs to.

+8.4%
Median return since issue price
46.6%
Now trading below their issue price

Neither figure is a forecast for this issue — they describe what happened to comparable issues. Full cohort analytics →

What we hold for this issue

Stated up front on every issue, so a sparse page reads as a fact about the source rather than a broken one.

Category split — who bidNot available from NSE for this issue
How demand built over time32 readings held — our own series
Price-point demand curveCumulative bids at each price in the band
Lead managers and registrar1 bank
Official documents3 documents
Listing-day priceOpened at ₹99 on debut
Performance since listingComputed from our own daily closes

What could go wrong

All 14risks & documents →
SevereTitle dispute on hospital Block-1 (Waqf/Central Government)p. 36
SevereSingle-hospital concentration — 100% revenue from Ferozepurp. 32
SevereTrade receivables ballooning far faster than revenuep. 65

From the register read out of the issuer’s own prospectus — each item is quoted verbatim with its page on the risks tab.

Led by Fedex Securities Private Limited — median +12.4% across the 18 of its issues we can price. All lead managers →

What happens when

20 AugPre-apply
24 AugBidding opens
27 AugBidding closes
31 AugAllotment
31 AugRefunds
1 SeptListing
8 OctMandate ends

Next: the UPI mandate expires on 8 Oct 2026.

What to watch

  • Priced at 14.5× earnings — 44% below the median of the peers the issuer itself names.
  • The register's top risk: Title dispute on hospital Block-1 (Waqf/Central Government) (prospectus page 36).
  • Its cohort's record: median +8.4% since issue price, 46.6% now below it — a base rate, not a forecast.

Each line restates a disclosure from the prospectus or the exchanges — nothing here is a recommendation to apply to this issue.

Track ABH HEALTHCARE LIMITED

Results, orders, board decisions and every other filing — summarised and sent to your WhatsApp the minute they are out.

Open the company page

Figures are as published by the exchanges and the issuer’s prospectus. MarketPing publishes facts, comparisons and history only — nothing here is a recommendation to apply to this issue, and we do not publish grey market premium.